Clovis Oncology, Inc. Deferred Tax Assets, Valuation Allowance
Clovis Oncology, Inc. had Deferred Tax Assets, Valuation Allowance of $873.90 million as of 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2022-02-24
- 2021-12-31: Deferred Tax Assets, Valuation Allowance $873.90M.
- 2020-12-31: Deferred Tax Assets, Valuation Allowance $806.62M.
- 2019-12-31: Deferred Tax Assets, Valuation Allowance $750.51M.
- 2018-12-31: Deferred Tax Assets, Valuation Allowance $647.89M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2021-12-31 | $873.90M 10-K · filed 2022-02-24 |
| 2020-12-31 | $806.62M 10-K · filed 2022-02-24 |
| 2019-12-31 | $750.51M 10-K · filed 2021-02-25 |
| 2018-12-31 | $647.89M 10-K · filed 2020-02-26 |
| 2017-12-31 | $564.12M 10-K · filed 2019-02-28 |
| 2016-12-31 | $592.42M 10-K · filed 2018-02-27 |
| 2015-12-31 | $449.08M 10-K · filed 2017-02-23 |
| 2014-12-31 | $259.00M 10-K · filed 2016-02-29 |
| 2013-12-31 | $136.32M 10-K · filed 2015-02-27 |
| 2012-12-31 | $91.45M 10-K · filed 2014-02-28 |
| 2011-12-31 | $55.34M 10-K · filed 2013-03-14 |